Page 6 - Nasdaq Spro News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Spero Therapeutics (NASDAQ:SPRO – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports. According to Zacks, “Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. […]

Spero Therapeutics (NASDAQ:SPRO – Get Rating) will post its quarterly earnings results after the market closes on Thursday, March 31st. Analysts expect Spero Therapeutics to post earnings of ($0.81) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link. Shares of Spero Therapeutics stock […]